Home › Funds › Farallon Capital Management › PCVX
Farallon Capital Management position in PCVX
VAXCYTE INC · Health Care
Latest position (Q1 2026)1.26M sh
Reported value held$73.28M
Portfolio Weight0.48%
First reportedQ4 2023
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 3.40K | $213.52K | New |
| Q1 2024 | 377.40K | $25.78M | Add |
| Q2 2024 | 290.00K | $21.90M | Reduce |
| Q3 2024 | 28.00K | $3.20M | Reduce |
| Q4 2025 | 5.00K | $230.70K | New |
| Q1 2026 | 1.26M | $73.28M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding PCVX
- Fidelity Management & Research (FMR) 20.85M sh · $1.21B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- BlackRock Inc 12.07M sh · $701.52M · Q2 2026
- Vanguard Group 12.19M sh · $562.63M · Q4 2025
- Wellington Management Group 7.00M sh · $407.00M · Q2 2026
- Geode Capital Management 3.46M sh · $201.13M · Q2 2026
- D. E. Shaw & Co 1.90M sh · $110.56M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Charles Schwab Investment Management 1.46M sh · $85.15M · Q2 2026
- Goldman Sachs Group 1.38M sh · $79.98M · Q2 2026
- Northern Trust Corp 1.28M sh · $74.42M · Q2 2026
- Norges Bank Investment Management 1.25M sh · $72.42M · Q2 2026